Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate

    NEXT STORY
    Bone Therapeutics announces results of Annual General Meeting
    PREV STORY
    Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017

    On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in ...

    author_avatar
    NASDAQ Market News

    Canadian Celiac Association offers up to $30,000 for celiac disease research

    author_avatar
    NASDAQ Market News

    Philips showcases integrated radiation oncology portfolio to provide a confident path to treatment at ASTRO 2019

    author_avatar
    NASDAQ Market News